Short answer

Erasca, Inc. (ERAS) filed its fiscal 2025 10-K annual report with the SEC on Mar 12, 2026.

Top risk flagged: Regulatory risk from compliance with EU Clinical Trials Regulation (CTR) effective January 31, 2025 impacting multi-center trial approvals

FY2025 key financial metrics · XBRL

Source: XBRL data from the Erasca, Inc. (ERAS) FY2025 10-K on SEC EDGAR. USD.

AI summary of each section, grounded in the filing text

Core business: Precision oncology company focused exclusively on discovering and developing therapies targeting RAS/MAPK pathway-driven cancers
New emphasis: Clinical-stage programs ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor) initiated INDs May 2025, first clinical data expected H1/H2 2026
Strategic shift: Termination of Novartis naporafenib license in June 2026 to prioritize differentiated RAS-targeting franchise development
Quantitative metric: Addressing ~2.7 million annual global patients with RAS-mutant tumors, including over 2.2 million with KRAS mutations targeted by ERAS-4001
Noteworthy fact: ERAS-0015 shows 8-21x higher cyclophilin A affinity and 5x more potent RAS inhibition preclinically versus leading competitor molecular glue

No revenue generated; net loss $124.5M in 2025 vs $161.7M in 2024, improving by $37.1M
Operating expenses down to $140.9M in 2025 from $179.6M in 2024; R&D expense 22% lower at $92.9M vs $115.4M
Best segment: ERAS-0015 R&D expense up to $26.9M from $6.7M; worst segment other clinical programs down from $58.3M to $32.8M
Cash and equivalents $341.8M as of Dec 31, 2025; raised $242.7M net in Jan 2026 offering; $150M payment to Joyo in March 2026
Expect Phase 1 data readouts 1H 2026 for ERAS-0015 and ERAS-4001; anticipate increased R&D and G&A expenses; cash sufficient through 2H 2028

Regulatory risk from compliance with EU Clinical Trials Regulation (CTR) effective January 31, 2025 impacting multi-center trial approvals
Geopolitical risk from potential delays and cost increases due to evolving U.S. tariff and import/export regulations affecting operations
Operational risk in dependency on third-party contract manufacturing organizations (CMOs) for clinical and potential commercial product supply
Competitive risk from rapid technological advances in biopharma potentially rendering Erasca's RAS/MAPK pathway approach obsolete
Financial risk with $892.2M accumulated deficit and need for substantial capital beyond $242.7M raised in 2026 offering to fund operations into second half 2028

Generated from the filing text; verify against the original. How to read a 10-K

Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.